Xiaochaihu Granules for Depression After Allogeneic Hematopoietic Stem Cell Transplantation
A Single-Center, Prospective, Randomized, Parallel-Assignment, Phase II Study Evaluating Two Dose Levels of Xiaochaihu Granules for Depression After Allogeneic Hematopoietic Stem Cell Transplantation
This is a single-center, prospective, randomized, dose-escalation Phase II clinical study. A total of 46 patients with newly diagnosed depression following allogeneic hematopoietic stem cell transplantation (allo-HSCT) will be enrolled.
Participants will be randomly assigned to receive different doses of Xiaochaihu Granules in addition to standard post-transplant care for 100 days. The primary objective is to evaluate the efficacy of Xiaochaihu Granules in improving depressive symptoms. Secondary objectives include assessment of safety and clinical outcomes such as event-free survival (EFS), graft-versus-host disease (GVHD), infections, and other transplantation-related complications.
Studienübersicht
Status
Intervention / Behandlung
Detaillierte Beschreibung
This is a single-center, prospective, randomized, dose-escalation Phase II clinical trial designed to evaluate the efficacy and safety of Xiaochaihu Granules in patients with depression following allogeneic hematopoietic stem cell transplantation (allo-HSCT).
A total of 46 eligible patients with newly diagnosed depression after allo-HSCT will be enrolled. Participants will be randomly assigned to receive either a low-dose or high-dose regimen of Xiaochaihu Granules, administered orally twice daily for 100 days, in addition to standard post-transplant care.
The primary endpoints include changes in depression severity as assessed by validated scales (e.g., HADS and HAMD) and changes in symptom burden. Secondary endpoints include event-free survival (EFS), incidence of graft-versus-host disease (GVHD), infections, viral reactivation, engraftment outcomes, and overall safety.
Studientyp
Einschreibung (Geschätzt)
Phase
- Phase 2
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
- Kind
- Erwachsene
- Älterer Erwachsener
Akzeptiert gesunde Freiwillige
Beschreibung
Inclusion Criteria:
Participants must meet all of the following criteria:
- Able to understand the study procedures and voluntarily provide written informed consent (or consent from a legal guardian where applicable);
- Age ≥14 years, male or female;
- Patients who have undergone allogeneic hematopoietic stem cell transplantation (allo-HSCT);
- Newly diagnosed depression after allo-HSCT, assessed by standardized scales (e.g., HADS and/or HAMD);
- Evidence of successful neutrophil engraftment prior to enrollment;
- Willing and able to comply with study procedures and follow-up assessments.
Exclusion Criteria:
- Refusal to participate in the study;
- Presence of severe psychiatric disorders or severe somatic symptom disorders;
- Known allergy to Xiaochaihu Granules or any of its components;
- Current use of other antidepressant medications;
Severe organ dysfunction or unstable clinical condition, including but not limited to:
Uncontrolled bloodstream infection; Expected survival <3 months;
- History of splenectomy;
- Renal insufficiency with serum creatinine ≥2.0 mg/dL;
- Cholestatic liver disease or unresolved hepatic veno-occlusive disease (VOD);
Significant cardiovascular conditions, including:
Unstable angina; Acute myocardial infarction within 6 months prior to enrollment; NYHA class III-IV heart failure; Circulatory failure requiring vasoactive or inotropic support; Clinically significant arrhythmia requiring treatment;
- Severe respiratory disease requiring mechanical ventilation or ≥50% oxygen support;
- Patients whose primary disease is in complete remission after transplantation (per protocol definition);
- Participation in another interventional clinical trial within 21 days prior to enrollment (or within 5 half-lives of the investigational product, whichever is longer);
- Any other condition deemed by the investigator to make the patient unsuitable for participation.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Low-dose group
On the basis of conventional standard treatment, apply the Shaoyang harmonizing method--low-dose group: Xiao Chai Hu Granules 10g, twice daily;
|
Xiaochaihu Granules 10 g, orally administered twice daily (BID) for 100 days, in addition to standard post-transplant care.
|
|
Aktiver Komparator: High-dose group
Xiao Chai Hu Granules 20g, twice daily, dissolved in water,
|
Xiaochaihu Granules 20 g, orally administered twice daily (BID) for 100 days, in addition to standard post-transplant care.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Change in Hospital Anxiety and Depression Scale (HADS) score
Zeitfenster: Baseline to Day 100
|
Change in HADS total score from baseline to Day 100.
The HADS is a validated self-reported scale ranging from 0 to 42, with higher scores indicating more severe anxiety and depression symptoms.
|
Baseline to Day 100
|
|
Change in Hamilton Depression Rating Scale (HAMD) score
Zeitfenster: Baseline to Day 100
|
Change in HAMD score from baseline to Day 100.
The HAMD is a clinician-administered scale assessing depression severity, with higher scores indicating more severe depressive symptoms.
|
Baseline to Day 100
|
|
Change in Traditional Chinese Medicine (TCM) syndrome score
Zeitfenster: Baseline to Day 100
|
Change in TCM syndrome score based on a standardized scoring system evaluating symptoms such as appetite, mood, sleep, and somatic complaints.
Higher scores indicate more severe syndrome manifestations.
|
Baseline to Day 100
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Event-Free Survival (EFS)
Zeitfenster: Up to Day 100
|
Time from treatment initiation to the occurrence of any predefined event, including disease progression, relapse, or death from any cause.
|
Up to Day 100
|
|
Incidence of Graft-versus-Host Disease (GVHD)
Zeitfenster: Up to Day 100
|
Incidence of acute or chronic GVHD diagnosed according to standard clinical criteria.
|
Up to Day 100
|
|
Incidence of infections
Zeitfenster: Up to Day 100
|
Occurrence of clinically or microbiologically confirmed infections during the study period.
|
Up to Day 100
|
|
Cytomegalovirus (CMV) and Epstein-Barr virus (EBV) reactivation
Zeitfenster: Up to Day 100
|
Incidence of CMV or EBV reactivation detected by laboratory testing (e.g., PCR).
|
Up to Day 100
|
|
Number of participants with hepatic veno-occlusive disease (VOD) diagnosed according to EBMT criteria
Zeitfenster: Up to Day 100 after transplantation
|
The number of participants who develop hepatic veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) after allo-HSCT, diagnosed according to the European Society for Blood and Marrow Transplantation (EBMT) clinical criteria, including bilirubin elevation, weight gain, hepatomegaly, ascites, or related clinical findings.
|
Up to Day 100 after transplantation
|
|
Time to neutrophil and platelet engraftment after allo-HSCT
Zeitfenster: Up to Day 100 after transplantation
|
Neutrophil engraftment is defined as the first of 3 consecutive days with an absolute neutrophil count (ANC) ≥ 0.5 × 10^9/L without growth factor support.
Platelet engraftment is defined as the first of 7 consecutive days with platelet count ≥ 20 × 10^9/L without platelet transfusion support.
Time to engraftment will be calculated from transplantation to the date of engraftment.
|
Up to Day 100 after transplantation
|
Mitarbeiter und Ermittler
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- OMD-HSCT-20250902
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .